Advances in and prospects of immunotherapy for prostate cancer
Cancer Letters · 2024-10 · 601 · 217155
DOI: 10.1016/j.canlet.2024.217155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-10. Verfasst von Deng Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Southwest Hospital, Army Medical University, Chongqing, 400038, China; Bioengineering College, Chongqing University, Chongq…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Tumor Microenvironment, Immunotherapy, Cancer Vaccines. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immunotherapy has shown promising therapeutic effects in hematological malignancies and certain solid tumors and has emerged as a critical and highly potential treatment modality for cancer. However, prostate cancer falls under the category of immune-resistant cold tumors, for which immunotherapy exhibits limited efficacy in patients with solid tumors. Thus, it is important to gain a deeper understanding of the tumor microenvironment in prostate cancer to facilitate immune system activation and overcome immune suppression to advance immunotherapy for prostate cancer. In this review, we discuss the immunosuppressive microenvironment of prostate cancer, which is characterized by the presence of few tumor-infiltrating lymphocytes, abundant immunosuppressive cells, low immunogenicity, and a noninflammatory phenotype, which significantly influences the efficacy of immunotherapy for prostate cancer. Immunotherapy is mainly achieved by activating the host immune system and overcoming immunosuppression. In this regard, we summarize the therapeutic advances in immune checkpoint blockade, immunogenic cell death, reversal of the immunosuppressive tumor microenvironment, tumor vaccines, immune adjuvants, chimeric antigen receptor T-cell therapy, and overcoming penetration barriers in prostate cancer, with the aim of providing novel research insights and approaches to enhance the effectiveness of immunotherapy for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, Southwest Hospital, Army Medical University, Chongqing, 400038, China; Bioengineering College, Chongqing University, Chongqing, 400044, China.
- Department of Urology, Daping Hospital, Army Medical University, Chongqing, 400042, China. Electronic address: wangluofu@aliyun.com.
- Department of Ultrasound, Southwest Hospital, Army Medical University, Chongqing, 400038, China. Electronic address: guoyanli@tmmu.edu.cn.
Zitieren
APA
Liu, D., Wang, L., & Guo, Y. (2024). Advances in and prospects of immunotherapy for prostate cancer. Cancer Letters, 601, 217155. https://doi.org/10.1016/j.canlet.2024.217155
Vancouver
Liu D, Wang L, Guo Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Letters. 2024;601:217155. doi:10.1016/j.canlet.2024.217155
BibTeX
@article{Liu2024,
author = {Liu, Deng and Wang, Luofu and Guo, Yanli},
title = {Advances in and prospects of immunotherapy for prostate cancer},
journal = {Cancer Letters},
year = {2024},
volume = {601},
pages = {217155},
doi = {10.1016/j.canlet.2024.217155}
}
EUVIMED